Page last updated: 2024-12-05

phosphoglycolohydroxamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phosphoglycolohydroxamate (PGH) is a synthetic compound that acts as a potent inhibitor of various enzymes involved in the biosynthesis of purines and pyrimidines. It is known to inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT), an essential enzyme in the purine biosynthesis pathway. PGH's inhibitory effect on GARFT is highly specific and has been shown to effectively block the production of purines. This inhibition leads to a depletion of cellular nucleotide pools, ultimately hindering cell growth and proliferation. Studies on PGH have focused on its potential as an anti-cancer agent due to its ability to target key metabolic pathways involved in tumor cell growth and survival. The compound's mechanism of action, its selectivity for GARFT, and its impact on purine biosynthesis make it an intriguing target for further research in the development of novel cancer therapies.'

phosphoglycolohydroxamate: inhibits DHAP (dihydroxyacetone phosphate)-converting enzymes; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phosphoglycolohydroxamic acid : The hydroxamate of phosphoglycolic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4797
CHEMBL ID371668
CHEBI ID28475
SCHEMBL ID4309631
MeSH IDM0053127

Synonyms (22)

Synonym
acetamide, n-hydroxy-2-(phosphonooxy)-
PGH ,
phosphoglycolohydroxamic acid
1TRD
1IK4
DB02739
1TPW ,
DB03026
phosphoglycolohydroxamate
2-(hydroxyamino)-2-oxoethyl dihydrogen phosphate
CHEBI:28475 ,
51528-59-7
bdbm50167777
CHEMBL371668 ,
phosphoric acid monohydroxycarbamoylmethyl ester
SCHEMBL4309631
DTXSID90199497
Q27093998
2-(hydroxyamino)-2-oxoethyldihydrogenphosphate
[(hydroxycarbamoyl)methoxy]phosphonic acid
HY-148077
CS-0610369
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 5.3.1.1 (triose-phosphate isomerase) inhibitorAny EC 5.3.1.* (intramolecular oxidoreductase interconverting aldoses and ketoses) inhibitor that interferes with the action of a triose-phosphate isomerase (EC 5.3.1.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
amidoalkyl phosphate
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Methylglyoxal SynthaseEscherichia coliKi0.03900.03900.03900.0390AID977610
Chain F, Methylglyoxal SynthaseEscherichia coliKi0.03900.03900.03900.0390AID977610
Chain B, TRIOSEPHOSPHATE ISOMERASETrypanosoma brucei bruceiKi4.00004.00004.00004.0000AID977610
Fructose-bisphosphate aldolase AOryctolagus cuniculus (rabbit)Ki1.00001.00001.00001.0000AID257659
Fructose-bisphosphate aldolase class 2Escherichia coli K-12Ki0.01000.01000.01000.0100AID257660
Triosephosphate isomeraseHomo sapiens (human)Ki3.50003.00003.50004.0000AID292822; AID594834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
glycolytic processFructose-bisphosphate aldolase class 2Escherichia coli K-12
glycolytic processFructose-bisphosphate aldolase class 2Escherichia coli K-12
gluconeogenesisFructose-bisphosphate aldolase class 2Escherichia coli K-12
gluconeogenesisTriosephosphate isomeraseHomo sapiens (human)
methylglyoxal biosynthetic processTriosephosphate isomeraseHomo sapiens (human)
glyceraldehyde-3-phosphate biosynthetic processTriosephosphate isomeraseHomo sapiens (human)
canonical glycolysisTriosephosphate isomeraseHomo sapiens (human)
glycolytic processTriosephosphate isomeraseHomo sapiens (human)
glycerol catabolic processTriosephosphate isomeraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
fructose-bisphosphate aldolase activityFructose-bisphosphate aldolase class 2Escherichia coli K-12
protein bindingFructose-bisphosphate aldolase class 2Escherichia coli K-12
zinc ion bindingFructose-bisphosphate aldolase class 2Escherichia coli K-12
lyase activityFructose-bisphosphate aldolase class 2Escherichia coli K-12
identical protein bindingFructose-bisphosphate aldolase class 2Escherichia coli K-12
protein homodimerization activityFructose-bisphosphate aldolase class 2Escherichia coli K-12
metal ion bindingFructose-bisphosphate aldolase class 2Escherichia coli K-12
triose-phosphate isomerase activityTriosephosphate isomeraseHomo sapiens (human)
protein bindingTriosephosphate isomeraseHomo sapiens (human)
methylglyoxal synthase activityTriosephosphate isomeraseHomo sapiens (human)
ubiquitin protein ligase bindingTriosephosphate isomeraseHomo sapiens (human)
protein homodimerization activityTriosephosphate isomeraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolFructose-bisphosphate aldolase class 2Escherichia coli K-12
cytosolFructose-bisphosphate aldolase class 2Escherichia coli K-12
extracellular spaceTriosephosphate isomeraseHomo sapiens (human)
nucleusTriosephosphate isomeraseHomo sapiens (human)
cytosolTriosephosphate isomeraseHomo sapiens (human)
extracellular exosomeTriosephosphate isomeraseHomo sapiens (human)
cytosolTriosephosphate isomeraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1811Experimentally measured binding affinity data derived from PDB2001Biochemistry, Jun-12, Volume: 40, Issue:23
Mechanistic implications of methylglyoxal synthase complexed with phosphoglycolohydroxamic acid as observed by X-ray crystallography and NMR spectroscopy.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Biochemistry, Jun-12, Volume: 40, Issue:23
Mechanistic implications of methylglyoxal synthase complexed with phosphoglycolohydroxamic acid as observed by X-ray crystallography and NMR spectroscopy.
AID292822Inhibition of triosephosphate isomerase2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase.
AID68946Selectivity (Ki rabbit /Ki yeast) of inhibitors for class II versus class I FBP aldolase2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases.
AID292820Inhibition of class I FBA2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase.
AID68939In vitro binding affinity towards FBP aldolase from yeast2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases.
AID257659Inhibitory activity against class I FBP aldolase from rabbit2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
N-Sulfonyl hydroxamate derivatives as inhibitors of class II fructose-1,6-diphosphate aldolase.
AID257660Inhibitory activity against class II FBP aldolase from Escherichia coli2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
N-Sulfonyl hydroxamate derivatives as inhibitors of class II fructose-1,6-diphosphate aldolase.
AID238281Binding affinity against class II fructose-bisphosphate aldolase2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
New inhibitors of rabbit muscle triose-phosphate isomerase.
AID292821Inhibition of class II FBA2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase.
AID68942In vitro binding towards FBP aldolase from rabbit2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases.
AID594834Inhibition of Triosephosphate isomerase2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.
AID292823Inhibition of rabbit muscle NADH-dependent cytosolic glycerophosphate dehydrogenase2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase.
AID238454Binding affinity against rabbit muscle triose-phosphate isomerase2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
New inhibitors of rabbit muscle triose-phosphate isomerase.
AID1811Experimentally measured binding affinity data derived from PDB1993Proteins, Aug, Volume: 16, Issue:4
Structures of the "open" and "closed" state of trypanosomal triosephosphate isomerase, as observed in a new crystal form: implications for the reaction mechanism.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1993Proteins, Aug, Volume: 16, Issue:4
Structures of the "open" and "closed" state of trypanosomal triosephosphate isomerase, as observed in a new crystal form: implications for the reaction mechanism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.57)18.7374
1990's10 (35.71)18.2507
2000's9 (32.14)29.6817
2010's8 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.10 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index5.47 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]